KEYTRUDA and KEYTRUDA QLEX, Plus Paclitaxel ± Bevacizumab, Approved for 2L/3L PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma February 17, 2026
Encouraging Patient Survival Observations Reported in Ovarian Cancer Lira-cel CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation February 17, 2026
Patient recruitment opened for Ph 1 trial of Innocell in patients with recurrent epithelial ovarian cancer February 9, 2026
Positive Results from Ph 1b/2 PESCO Trial of MVP-S, Keytruda and Cyclophosphamide in Recurrent Epithelial Ovarian Cancer (EOC) Reported February 1, 2026
Positive Results from Ph 1B/2 PESCO Trial of MVP-S with Keytruda and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC) Announced January 25, 2026
OS Primary Endpoint Met in Pivotal Ph 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer January 25, 2026
Sofetabart mipitecan receives US FDA Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer January 25, 2026
Vigil Demonstrates Significant Survival Benefit in cTMB-H/HRP Ovarian Cancer Patients; Ph 2b VITAL Trial Analysis Published in JCO – Precision Oncology January 18, 2026
Promising Data from Ongoing Ph 2a study for BI-1808 with KEYTRUDA in Recurrent Ovarian Cancer Reported January 11, 2026
Successful Pre-IND FDA Meeting and Continued Progress Toward First-in-Human Trial of ERNA-101 in Ovarian Cancer Announced January 11, 2026
FDA Fast Track Designation for ETX-19477 for BRCA-Mutated, Platinum-Resistant Ovarian Cancer Patients Announced January 11, 2026
Data Reported from Ongoing Ph 2a study for BI-1808 with KEYTRUDA in Recurrent Ovarian Cancer January 4, 2026
LIXTE Biotechnology, The University of Texas MD Anderson Cancer Center, and GSK expand collaboration on LB-100 to treat ovarian clear cell cancer December 30, 2025
DESTINY-Ovarian01 Ph 3 Trial of ENHERTU® Initiated as 1L Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer December 9, 2025
Tubulis announces Series C funding of €344M (US $401M) to initiate pivotal trials with lead ADC candidate TUB-040 November 4, 2025
Ph 2 study of BND-22 (SAR444881) + anti-PD-1 therapy in IO-refractory NSCLC or IO-naive MSS-CRC or ovarian cancer to be initiated October 16, 2025
New Ph 2 Data for Stenoparib/2X-121 Showed Landmark Median OS Surpassing 25 Months September 23, 2025
IMNN-001 Ph 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift September 23, 2025
Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Previously Treated with Bevacizumab September 16, 2025
FDA accepted relacorilant NDA for patients with platinum-resistant ovarian cancer; PDUFA date: Jul 11, 2026 September 16, 2025
First Patient Dosed in Ph 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer August 5, 2025
Final Clinical Data Update from the NXP800 Ph 1b Study in Ovarian Cancer Provided and Completion of the NXP900 Ph 1a Dose Escalation Study Reported August 5, 2025
